WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System.  Part IV: IPR & Heart Disease – Knocking Down Erroneously Extended Patents. Read the full story below: In 2017, the patent for an anti-clotting drug prasugrel, under […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Stresses Importance Of Next USPTO Director – This week, CAPA Executive Director Matthew Lane penned an op-ed in STAT News highlighting the crucial role that the next U.S. Patent and Trademark Office Director will have on reducing drug costs for millions of American patients, many of which are already struggling financially […]

Continue Reading

WHAT YOU NEED TO KNOW We’re two months into the new year and the Coalition Against Patent Abuse (CAPA) is continuing to highlight why Congress should act to address abuses of the U.S. patent system. Many Big Pharma companies regular engage in tactics that can extend government-granted monopolies and illegitimately keep drug prices high for […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System. Part II: IPR & Zytiga – Competition Matters – Here, CAPA looks at how the IPR proceeding for the prostate cancer medicine Zytiga accelerated patient access to generic […]

Continue Reading

WHAT YOU NEED TO KNOW BY THE NUMBERS – A new Morning Consult poll conducted for the Campaign for Sustainable Rx Pricing (CSRxP) – a member of CAPA – found that Americans overwhelmingly agree that it is time for Congress and the new Administration to reform the U.S. healthcare system to lower costs and put […]

Continue Reading

WHAT YOU NEED TO KNOW MUST READ: CAPA Warns Recent Federal Circuit Court Decision Could Erode Hatch-Waxman, Lead to Even Higher Drug Prices Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), recently authored an op-ed in Bloomberg Law around the Federal Circuit’s recent decision in GlaxoSmithKline LLCTeva Pharmaceuticals USA, Inc.: “The Federal Circuit’s decision in GlaxoSmithKline […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Files Amicus Brief Urging the Supreme Court to Preserve IPR to Lower Drug Prices. DID YOU KNOW – The U.S. Supreme Court is reviewing Arthrex Inc. v. Smith & Nephew Inc. to determine the constitutionality of the Patent Trial and Appeal Board (PTAB). In an amicus brief filed recently, CAPA outlined […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA: The USPTO must prioritize patent quality and restore the IPR system to its proper focus. UPDATE – As part of its ongoing campaign to safeguard the U.S. patent system and stop Big Pharma from gaming the system, CAPA filed comments this week with the United States Patent and Trademark Office (USPTO).  The […]

Continue Reading

WHAT YOU NEED TO KNOW BREAKING NEWS: CAPA releases guidance for next Administration and Congress encouraging Washington to address Big Pharma’s abuses of the patent system that keeps drug prices high for patients and the entire U.S. healthcare system.  Continued exploitations of the U.S. patent process results in deadweight losses that get saddled on the backs […]

Continue Reading

WHAT YOU NEED TO KNOW A must-read report was recently released – The 2020 Access and Savings Report by the Association for Accessible Medicines (AAM) – a member of CAPA – that highlights the critical benefits of increasing access to alternative prescription drugs which can drive affordability for not only American patients, but the healthcare system as […]

Continue Reading